Committee Opinion No. 641: Human Papillomavirus Vaccination.
Human papillomavirus (HPV) is associated with the development of anogenital cancer (including cervical, vaginal, vulvar, penile, and anal), oropharyngeal cancer, and genital warts. Human papillomavirus vaccination can significantly reduce the incidence of anogenital cancer and genital warts. Despite the benefits of HPV vaccines, only approximately one third of girls in the recommended age group have received all three vaccines. Compared with other vaccines recommended in the same age bracket, HPV vaccination rates in the United States are unacceptably low. It is crucial that obstetrician-gynecologists and other providers educate parents and patients on the benefits and safety of HPV vaccination. The Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists recommend routine vaccination with HPV vaccine for girls and boys. The 9-valent HPV vaccine is recommended by the Advisory Committee on Immunization Practices and was licensed by the U.S. Food and Drug Administration in December 2014 for girls and boys aged 11-12 years.
D000293:Adolescent; D000328:Adult; D026683:Advisory Committees / Q000592:standards; D000367:Age Factors; D001294:Attitude to Health; D002487:Centers for Disease Control and Prevention, U.S.; D005260:Female; D006801:Humans; D008297:Male; D020380:Needs Assessment; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D017751:Safety Management; D012737:Sex Factors; D012749:Sexually Transmitted Diseases / Q000517:prevention & control*; D014481:United States; D014611:Vaccination / Q000592:standards*; D055815:Young Adult
D053918:Papillomavirus Vaccines